An Ex Vivo Tissue Culture Model for Fibrovascular Complications in Proliferative Diabetic Retinopathy
January 25th, 2019
7.3K views
Here, we present a protocol to study the pathophysiology of proliferative diabetic retinopathy by using patient-derived, surgically-excised, fibrovascular tissues for three-dimensional native tissue characterization and ex vivo culture. This ex vivo culture model is also amenable for testing or developing new treatments.
Overview
This article presents a protocol for studying the pathophysiology of proliferative diabetic retinopathy using patient-derived fibrovascular tissues. The method allows for three-dimensional native tissue characterization and ex vivo culture, which is suitable for testing new treatments.
Key Study Components
Area of Science
- Neuroscience
- Ophthalmology
- Pathophysiology
Background
- Proliferative diabetic retinopathy is a significant cause of vision loss.
- Understanding its pathophysiology is crucial for developing effective treatments.
- Current models may not fully replicate the disease environment.
- Patient-derived tissues offer a more accurate representation of the disease.
Purpose of Study
- To develop a reliable ex vivo culture model for diabetic retinopathy.
- To characterize fibrovascular tissues from patients.
- To facilitate the testing of new therapeutic approaches.
Methods Used
- Collection of surgically-excised fibrovascular tissues from patients.
- Three-dimensional tissue characterization techniques.
- Ex vivo culture methods for maintaining tissue viability.
- Assessment of potential treatments on cultured tissues.
Main Results
- Successful establishment of an ex vivo culture model.
- Characterization of the native tissue architecture.
- Demonstrated feasibility for testing new treatments.
- Insights into the pathophysiological mechanisms of the disease.
Conclusions
- The developed model provides a valuable tool for research.
- It enhances understanding of diabetic retinopathy.
- Potential to accelerate the development of new therapies.
Frequently Asked Questions
What is proliferative diabetic retinopathy?
Proliferative diabetic retinopathy is a complication of diabetes that affects the eyes and can lead to vision loss.
How are fibrovascular tissues obtained?
Fibrovascular tissues are surgically excised from patients undergoing treatment for diabetic retinopathy.
What is the significance of ex vivo culture?
Ex vivo culture allows researchers to study tissues in a controlled environment, mimicking in vivo conditions.
Can this model be used for testing new treatments?
Yes, the ex vivo culture model is designed to facilitate the testing of new therapeutic approaches.
What are the potential benefits of this research?
This research may lead to better understanding and treatment options for patients with diabetic retinopathy.
Executive Industry Relevance
This ex vivo tissue culture model addresses a critical gap in diabetic retinopathy research by enabling direct study of human proliferative diabetic retinopathy pathophysiology using patient-derived fibrovascular tissue. It supports mechanistic de-risking and target validation by preserving native 3D tissue architecture and dynamic cell-ECM interactions. The model enhances predictive confidence in preclinical evaluation by allowing simultaneous assessment of molecular mechanisms, cellular processes, and treatment responses in a clinically relevant human tissue context.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of therapeutic hypotheses in native human PDR tissue, clarifying pathogenic pathways involved in fibrovascular lesion formation.
- Operational Value: Provides a reproducible system for functional target validation using surgically excised patient tissue, reducing reliance on surrogate models.
- Scientific Value: Supports mechanistic de-risking by elucidating dynamic cell-cell and cell-ECM interactions in 3D microenvironment that drive vascular proliferation and fibrosis.
Screening & Assay Development
- Scientific Value: Generates quantitative immunofluorescence readouts of endothelial sprouting (CD-31+) and vasculature preservation in response to angiogenic factors like VEGFA.
- Operational Value: Enables standardized preparation of tissue explants embedded in fibrin matrix for consistent 3D culture and imaging across experiments.
- Scientific Value: Facilitates assay development for screening modulators of pathological angiogenesis and fibrosis using end-point whole-mount immunofluorescence characterization.
Translational & Preclinical Research
- Scientific Value: Maintains disease-relevant system properties by using native human PDR tissue, ensuring translational continuity from discovery to preclinical validation.
- Operational Value: Allows longitudinal culture and treatment testing, supporting risk-adjusted advancement decisions based on tissue-level responses.
- Scientific Value: Enables evaluation of novel interventions on pathophysiological processes such as vascular sprouting and extracellular matrix remodeling in a human tissue context.
Pipeline & Workflow Integration
The model fits within the discovery continuum from target identification through preclinical evaluation, providing a human-relevant platform to de-risk targets before investment in animal studies or clinical candidates.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling direct observation of angiogenic and fibrotic processes in native human PDR tissue architecture.
- Screening: Delivers assay-ready tissue explants with quantitative immunofluorescence outputs for evaluating compound effects on vascular and cellular phenotypes.
- Analytics: Provides multiplexed immunofluorescence and nuclear staining readouts that allow comparative analysis of tissue composition and cellular activation states across conditions.
- Translational Research: Connects discovery findings to preclinical continuity by preserving patient-derived tissue characteristics critical for predicting clinical response.
- Enterprise Reuse: Establishes a reusable tissue culture platform for iterative testing of multiple targets or formulations using the same standardized embedding and imaging workflow.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by reducing mechanistic ambiguity through direct observation in human disease tissue.
- Operational Value: Promotes standardization and reproducibility via defined tissue dissection, fibrin embedding, and immunofluorescence protocols.
- Strategic Value: Improves go/no-go decision-making by providing human tissue-based efficacy and safety signals earlier in the discovery pipeline.
- Portfolio Impact: Enables risk-adjusted prioritization of candidates based on their effects on human PDR tissue pathophysiology, reducing late-stage biological attrition.
Implementation Considerations
- Requires expertise in microsurgical tissue handling, sterile culture techniques, and immunofluorescence microscopy.
- Dependent on access to surgically excised fibrovascular tissue from PDR patients and sterile fibrinogen/thrombin preparation.
- Necessitates standardization across teams for tissue dissection size, embedding consistency, and imaging parameters to ensure comparability.
- Involves adaptation considerations when extending the model to other ocular fibrovascular diseases or comparing across donor tissue variability.
- Limited by tissue availability and viability window post-excision, necessitating coordinated logistics with clinical partners for timely processing.
Biopharma FAQs
Why is null hypothesis testing important for validating targets in PDR fibrovascular tissue?
Null hypothesis testing enables rigorous evaluation of whether observed changes in endothelial sprouting or matrix deposition are statistically significant compared to controls, supporting confident target validation in human tissue.
How does isolating independent variables like VEGFA or TGF-β fit into the target discovery pipeline?
By adding specific factors such as VEGFA or TGF-β to the culture medium, researchers can isolate their individual effects on vascular sprouting and fibrosis, enabling mechanistic de-risking of pathway-specific targets.
What quantitative dependent variable measurements does the model enable for assessing treatment response?
The model enables quantification of CD-31-positive endothelial sprouting and vasculature preservation through whole-mount immunofluorescence, providing measurable endpoints for evaluating compound efficacy.
Why are replication requirements critical for ensuring cross-functional collaboration in target validation?
Replication across multiple tissue explants and donors ensures reproducibility of angiogenic and fibrotic responses, which is essential for aligning discovery, preclinical, and clinical teams on target credibility.
What statistical analysis capabilities are required before implementing this model in a discovery workflow?
Implementation requires the ability to perform comparative statistical analysis (e.g., t-tests or ANOVA) on immunofluorescence intensity or vessel count data to determine significant differences between treatment and control conditions.
Chapters in this video
0:04
Title
0:40
Fibrovascular Tissue Dissection
1:37
Casting Upright Fibrin Gel Droplets for the Characterization of Native FT and Ex Vivo Culture
2:52
Native FT and Ex Vivo Culture End-Point
3:19
Whole-Mount Immunofluorescence Staining
7:00
Results: PDR Ex Vivo Culture Induced Sprouting of CD31-positive Endothelium and Vasculature Preservation in Response to VEGFA
7:31
Conclusion
